FDA Approves Drug to Prevent Migraines Aimovig was approved on Thursday, become the first medicine of its kind — a once a month injection used to block a key molecule that starts migraines. In clinical trials, the FDA said most people experienced one less migraine a month after taking Aimovig. Research on migraines goes back to the 1980’s, in which it was found that sufferers had high levels of a protein called CGRP in their blood. Migraines can become debilitating to the point they create nausea, visual disturbances and light sensitivity. The drugmaker, Amgen, has set the list price at $6,900 a year.
